top of page
Search

Increased Risk of Death Associated with Pepaxto (melphalan flufenamide)

FDA is alerting patients and health care professionals that a clinical trial (OCEAN, Study OP-103) evaluating Pepaxto (melphalan flufenamide) with dexamethasone to treat patients with multiple myeloma showed an increased risk of death.

The trial compared Pepaxto with low-dose dexamethasone to pomalidomide with low-dose dexamethasone in patients with relapsed or refractory (resistant) multiple myeloma following 2-4 lines of prior therapy and in patients who were resistant to lenalidomide in the last line of therapy. #healthcare #health #medicine #diabetes #insulin

28 views

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page